Advertisement
About Masimo
Masimo (Nasdaq: MASI) develops innovative monitoring technologies thatsignificantly improve patient care -- helping solve "unsolvable" problems. In1995, the company debuted Measure-Through Motion and Low Perfusion pulseoximetry, known as Masimo SET, which virtually eliminated false alarms andincreased pulse oximetry's ability to detect life-threatening events. Morethan 100 independent and objective studies demonstrate Masimo SET provides themost reliable SpO2 and pulse rate measurements even under the most challengingclinical conditions, including patient motion and low peripheral perfusion. In2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthroughnoninvasive blood constituent monitoring platform that can measure many bloodconstituents that previously required invasive procedures. Rainbow SETcontinuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygencontent (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and(PVI(TM)), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusionindex (PI), allowing early detection and treatment of potentiallylife-threatening conditions. Founded in 1989, Masimo has the mission of"Improving Patient Outcomes and Reducing Cost of Care by Taking NoninvasiveMonitoring to New Sites and Applications." Additional information about Masimoand its products may be found at http://www.masimo.com.
Advertisement
Masimo, SET, Signal Extraction Technology, Improving Outcomes and ReducingCost of Care by Taking Noninvasive Monitoring to New Sites and Applications,Rainbow, SpHb, SpCO, SpMet, PVI, Pulse CO-Oximetry and PulseCO-Oximeter are trademarks or registered trademarks of Masimo Corporation.Masimo Corporation Investor Contact: Mark P. de Raad Executive Vice President and Chief Financial Officer Masimo Corporation (949) 297-7080 [email protected] Media Contact: Dana Banks Manager, Public Relations Masimo Corporation (949) 297-7348 [email protected]
SOURCE Masimo Corporation
